Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation on Long‐Term Dialysis
Pacing and Clinical Electrophysiology · 2025
DOI: 10.1111/pace.15208 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Pacing and Clinical Electrophysiology, 2025. Verfasst von Kenji Hashimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Westmead Applied Research Centre, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Renal Dialysis, Thromboembolism. Die Arbeit nennt 73 Literaturangaben.
Abstract (Originalsprache)
Background
Optimal strategies for thromboembolism prevention, including vitamin K antagonists (VKA), direct oral anticoagulants (DOAC), and left atrial appendage occlusion (LAAO), for patients with atrial fibrillation (AF) and on dialysis have not been fully investigated. We aimed to investigate the efficacy and safety of thromboembolism prevention strategies in AF patients on dialysis through a network meta‐analysis.
Methods
Multiple databases were searched through January 2024. The primary efficacy endpoint was thrombotic events, defined as ischemic stroke or systemic thromboembolism, whereas the primary safety endpoint was major bleeding. These strategies were ranked using P ‐scores.
Results
Our study identified 28 eligible studies (including 3 randomized controlled trials) that enrolled 144,630 AF patients on dialysis. The risks of thrombotic events in any DOAC and VKA were comparable to no‐anticoagulant, whereas LAAO was associated with a lower risk of thrombotic events (HR [95% CI]: 0.19 [0.06–0.60]). Compared to no‐anticoagulant, VKA, regular‐dose rivaroxaban, and dabigatran were associated with a higher risk of major bleeding, but rivaroxaban 10 mg daily, and apixaban 2.5 or 5 mg twice daily were not. LAAO, rivaroxaban 10 mg daily and apixaban 2.5 or 5 mg twice daily were highly ranked in efficacy and safety outcomes.
Conclusions
LAAO may possibly be the reasonable therapeutic option for AF patients on dialysis, but rivaroxaban 10 mg daily and apixaban 2.5 or 5 mg twice daily can also be considered. Further studies are warranted to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Westmead Applied Research Centre, University of Sydney, Sydney, New South Wales, Australia.
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Digital Health, Social Medicine Group, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
- Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
ORCID-Profile: Kenji Hashimoto, Tadao Aikawa, Alexandros Briasoulis
Zitieren
APA
Hashimoto, K., Fujisaki, T., Aikawa, T., Iwagami, M., Miyamoto, Y., Slipczuk, L., Biase, L. D., Briasoulis, A., Yasuhara, J., Takagi, H., & Kuno, T. (2025). Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation on Long‐Term Dialysis. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15208
Vancouver
Hashimoto K, Fujisaki T, Aikawa T, Iwagami M, Miyamoto Y, Slipczuk L, et al. Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation on Long‐Term Dialysis. Pacing and Clinical Electrophysiology. 2025. doi:10.1111/pace.15208
BibTeX
@article{Hashimoto2025,
author = {Hashimoto, Kenji and Fujisaki, Tomohiro and Aikawa, Tadao and Iwagami, Masao and Miyamoto, Yoshihisa and Slipczuk, Leandro and Biase, Luigi Di and Briasoulis, Alexandros and Yasuhara, Jun and Takagi, Hisato and Kuno, Toshiki},
title = {Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation on Long‐Term Dialysis},
journal = {Pacing and Clinical Electrophysiology},
year = {2025},
doi = {10.1111/pace.15208}
}
EUVIMED